
RNAC Stock Forecast & Price Target
RNAC Analyst Ratings
Bulls say
Cartesian Therapeutics Inc. demonstrated a positive outlook stemming from recent clinical advancements, specifically the Phase 2b data showing sustained clinically meaningful improvements with an average MG-ADL reduction of 4.8 at 12-month dosing intervals, outperforming existing FcRn antagonists. The safety profile of Descartes-08 has also been robust, with no observed severe adverse effects, which enhances its potential for broader patient adoption. Additionally, the mechanistic insights provided by correlative biomarkers indicate significant therapeutic benefits, further solidifying the company's innovative stance within the biopharmaceutical sector.
Bears say
Cartesian Therapeutics Inc. experienced a decrease in cash and cash equivalents, falling from $162.1 million in Q2 2025 to $145.1 million in Q3 2025, indicating a significant operating expenditure as the company advances its Phase 3 myasthenia gravis (MG) program. Despite the management's assertion that current cash reserves will fund operations through mid-2027, the market appears to ascribe little value to the company's prospects, as reflected by its low enterprise value of approximately $50 million, given its ongoing clinical programs and regulatory designations. Furthermore, the negative sentiment is exacerbated by a lack of confidence in the therapeutic options currently available for treating autoimmune conditions, as indicated by the underutilization of existing treatments among patients.
This aggregate rating is based on analysts' research of Cartesian Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RNAC Analyst Forecast & Price Prediction
Start investing in RNAC
Order type
Buy in
Order amount
Est. shares
0 shares